UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Journal of the American Academy of Dermatology, 2021-10, Vol.85 (4), p.863-872

2021

Volltextzugriff (PDF)

Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1305-1313

2020

Volltextzugriff (PDF)

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.572-582

2020

Volltextzugriff (PDF)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

American journal of clinical dermatology, 2021-07, Vol.22 (4), p.555-566

2021

Volltextzugriff (PDF)

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

Journal of the American Academy of Dermatology, 2023-05, Vol.88 (5), p.1008-1016

2023

Volltextzugriff (PDF)

Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies

Journal of the American Academy of Dermatology, 2023-03, Vol.88 (3), p.651-653

2023

Volltextzugriff (PDF)

Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis

Annals of allergy, asthma, & immunology, 2023-04, Vol.130 (4), p.500-507.e3

2023

Volltextzugriff (PDF)

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

American journal of clinical dermatology, 2024-07, Vol.25 (4), p.669-683

2024

Volltextzugriff (PDF)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, 2023-01, Vol.37 (1), p.137-146

2023

Volltextzugriff (PDF)

18263 Association between an itch-free state in atopic dermatitis treated with ruxolitinib cream and systemic inflammatory mediators

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB95-AB95

2020

Volltextzugriff (PDF)

27482 Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB148-AB148

2021

Volltextzugriff (PDF)

28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB179-AB179

2021

Volltextzugriff (PDF)

24916 Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: Pooled analysis from two randomized phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB50-AB50

2021

Volltextzugriff (PDF)

27620 Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB157-AB157

2021

Volltextzugriff (PDF)

27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB158-AB158

2021

Volltextzugriff (PDF)

27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB160-AB160

2021

Volltextzugriff (PDF)

26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB121-AB121

2021

Volltextzugriff (PDF)

26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB121-AB121

2021

Volltextzugriff (PDF)

28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB178-AB178

2021

Volltextzugriff (PDF)

27496 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB149-AB149

2021

Volltextzugriff (PDF)

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Skin (Milwood, N.Y.), 2020-10, Vol.4 (6), p.s95

2020

Volltextzugriff (PDF)

Non-Itchy Lichen Amyloidosus

International journal of dermatology, 1992-10, Vol.31 (10), p.747-747

1992

Volltextzugriff (PDF)

Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes

Nature immunology, 2010-05, Vol.11 (5), p.427-434

2010

Volltextzugriff (PDF)

Podoplanin-Rich Stromal Networks Induce Dendritic Cell Motility via Activation of the C-type Lectin Receptor CLEC-2

Immunity (Cambridge, Mass.), 2012-08, Vol.37 (2), p.276-289

2012

Volltextzugriff (PDF)

Ensemble Tropical Rainfall Potential (eTRaP) Forecasts

Weather and forecasting, 2011-04, Vol.26 (2), p.213-224

2011

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(29)
Buchkapitel
(1)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies

Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis

18263 Association between an itch-free state in atopic dermatitis treated with ruxolitinib cream and systemic inflammatory mediators

27482 Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies

24916 Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: Pooled analysis from two randomized phase 3 studies

27620 Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies

27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies

26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies

26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies

28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies

27496 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Non-Itchy Lichen Amyloidosus

Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes

Podoplanin-Rich Stromal Networks Induce Dendritic Cell Motility via Activation of the C-type Lectin Receptor CLEC-2

Ensemble Tropical Rainfall Potential (eTRaP) Forecasts

Suchergebnisse filtern